Floatz logo

Telaglenastat

Metastatic Lung Non-Small Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Metastatic Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Vesanoid
Peking University People's Hospital
Phase 3BB
Tak-228
Faeth Therapeutics
Phase 2BB
Eribulin
M.D. Anderson Cancer Center
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2B

View all 20 →

Same molecule, other indications

Telaglenastat is also rated in:

renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →
nonpapillary renal cell carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →